{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:06 23:25:58.836",
            "Expression": "mesenchymal PN-101",
            "NStudiesAvail": 430108,
            "NStudiesFound": 1,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 1,
            "FieldList": [
                  "ResultsFirstSubmitDate",
                  "ResultsFirstSubmitQCDate",
                  "RetractionPMID",
                  "RetractionSource",
                  "SamplingMethod",
                  "SecondaryId",
                  "SecondaryIdDomain",
                  "SecondaryIdLink",
                  "SecondaryIdType",
                  "SecondaryOutcomeDescription",
                  "SecondaryOutcomeMeasure",
                  "SecondaryOutcomeTimeFrame",
                  "SeeAlsoLinkLabel",
                  "SeeAlsoLinkURL",
                  "SeriousEventAssessmentType",
                  "NCTId"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Assessment of IMACS-TIS at week 4 after the IP administration. Total Improvement Score (TIS) based on absolute percentage change is assessed scale 0 to 100. Higher score indicates greater improvement.",
                              "Assessment of IMACS-TIS at week 8 after the IP administration. Total Improvement Score (TIS) based on absolute percentage change is assessed scale 0 to 100. Higher score indicates greater improvement.",
                              "Proportion of subjects with the IMACS-TIS \u2265 20 at week 12 after the IP administration.",
                              "Changes in CSAM for the IMACS assessed at week 4, week 8 and week 12 after the IP administration from the baseline (Visit 2).",
                              "Changes in CDASI assessed at week 4, week 8 and week 12 after the IP administration from the baseline (Visit 2) for dermatomyositis only.",
                              "Changes in PPNRS assessed at week 4, week 8 and week 12 after the IP administration from the baseline (Visit 2) for dermatomyositis only. The intensity of pruritis is assessed on a patient reported scale 0 to 10."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "International Myositis And Clinical Studies group-Total Improvement Score(IMACS-TIS)",
                              "International Myositis And Clinical Studies group-Total Improvement Score(IMACS-TIS)",
                              "Response rate of IMACS-TIS",
                              "Changes of Core Set Activity Measures(CSAM)",
                              "Changes of Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI)",
                              "Changes of Peak Pruritus Numeral Rating Scale(PPNRS)"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "4 weeks after the IP administration",
                              "8 weeks after the IP administration",
                              "12 weeks after the IP administration",
                              "Visit 2(Day 1), Visit 5(4 weeks), Visit 6(8 weeks), Visit 7(12 weeks)",
                              "Visit 2(Day 1), Visit 5(4 weeks), Visit 6(8 weeks), Visit 7(12 weeks)",
                              "Visit 2(Day 1), Visit 5(4 weeks), Visit 6(8 weeks), Visit 7(12 weeks)"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04976140"
                        ]
                  }
            ]
      }
}